235
Participants
Start Date
March 8, 2023
Primary Completion Date
June 12, 2023
Study Completion Date
July 5, 2023
HSK16149 capsule
Subjects will be given 40mg or 60mg of HSK16149 orally.
Placebo
Subjects will be given HSK16149 placebo orally.
Dongguan People's Hospital, Dongguan
Foshan Fuxing Chancheng Hospital, Foshan
The First Affiliated Hospital of Jinan University, Guangzhou
Affiliated Hospital of Guizhou Medical University, Guiyang
Beijing Jishuitan Hospital Guizhou Hospital, Guiyang
Zunyi University Affiliated Hospital, Zunyi
Henan Provincial People's Hospital, Zhengzhou
People's Hospital of Wuhan University, Wuhan
Wuhan Central Hospital, Wuhan
Xiangya Third Hospital of Central South University, Changsha
The First Affiliated Hospital of South China University, Hengyang
Lianyungang First People's Hospital, Lianyungang
Nanjing First Hospital, Nanjing
Chengdu Second People's Hospital, Chengdu
Chengdu Third People's Hospital, Chengdu
Sichuan Provincial People's Hospital, Chengdu
Guangyuan First People's Hospital, Guangyuan
Mianyang Central Hospital, Mianyang
Yibin Second People's Hospital, Yibin
The First People's Hospital of Yunnan Province, Kunming
Sino-Japanese Friendship Hospital, Beijing
Haisco Pharmaceutical Group Co., Ltd.
INDUSTRY